Sign in
Taking people in United StatesPhase 2

Testing NVG-2089 given by infusion for adults with immune thrombocytopenia

Tests NVG-2089, a new drug, in adults with immune thrombocytopenia.

Key facts

Who runs it
Nuvig Therapeutics, Inc.
Where
Boston, Greenville, and Washington D.C., United StatesSee the 3 sitesAlso in 3 other countries, 10 sites
Registry title
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia
Status
Recruiting
Phase
Phase 2
People taking part
30 people, planned
Started
30 Sept 2025
Expected to end
31 Dec 2027
Type of study
Interventional
Treatments tested
  • NVG-2089
Record updated
14 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with primary immune thrombocytopenia (ITP), a low platelet count caused by the immune system. It tests the new drug NVG-2089, given into a vein.

Age
18 to 80 years
Sex
Men and women
Disease stage
Persistent (>3 months and ≤12 months) or chronic (>12 months) primary ITP. People must have no symptoms or only minor bleeding of the skin or mouth. Platelet count must be ≤50,000 cells/mm3 on 2 tests at least 5 days apart.
Earlier treatment
If treated for ITP before, people must have responded to at least one past therapy (platelets rising to ≥ 50,000 cells/mm3, an increase of ≥ 20,000 cells/mm3). If IVIg was used before, platelets must have doubled within 7 days, without losing response. In the US, if a screening platelet count is >30,000 and <50,000 cells/mm3, people must be on at least 1 other ITP treatment that is not working well enough. No IVIg, dexamethasone, transfusion or change in ITP therapy within 4 weeks. No rituximab or anti-CD20 agent within 6 months. No FcRn inhibitor within 12 weeks.
Biomarker or test result
Platelet count ≤50,000 cells/mm3 at screening.

Main reasons for not taking part

  • ITP caused by another illness or by medicines
  • Past removal of the spleen or past solid organ transplant
  • Active hepatitis B, hepatitis C or HIV
  • Serious infection, or poor blood, kidney or liver test results
  • Pregnant or breastfeeding women

The registry criteria, word for word

Show all 31 criteriaShow less

Who can take part

  • Males and female participants, age 18 to 80 years at time of screening
  • Diagnosis of persistent (>3 months and ≤12 months), or chronic (>12 months) primary ITP. If the participant has received prior treatment for ITP, they must have a history of response to at least one previous therapy (defined as increase in platelet count to ≥ 50,000 cells/mm3 with an increase of ≥ 20,000 cells/mm3 relative to platelet count prior to treatment)
  • Asymptomatic or with minor mucocutaneous bleeding AND platelet count of ≤50,000 cells/mm3, measured on 2 occasions at least 5 days apart during the screening period
  • (For US only) If at least one screening platelet count >30,000 cells/ mm3 and <50,000 cells/mm3, the participant must be on at least 1 other treatment for ITP with insufficient response as evidenced by platelet count <50,000 cells/ mm3
  • If participant has received prior IVIg therapy participant must have shown a sufficient platelet response (doubling from baseline platelet count within 7 days of IVIg infusion) and must not have lost response to IVIg therapy while on treatment
  • Female participants of childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day 1
  • Female participants who are sexually active with a male partner of reproductive potential must use double contraception (including a barrier contraceptive and another method) from at least 28 days prior to Screening and for 90 days after last dose of study drug; female participants must also refrain from oocyte donation for the purpose of reproduction during this period. Exceptions are made for surgically sterile participants, or post-menopausal females (defined as 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum follicle -stimulating hormone levels >40 mIU/mL or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy). Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the participant
  • Male participants with female partners who are of reproductive potential must agree to the use of highly effective, barrier contraception for the duration of the study, and for 90 days after the last dose of study drug
  • Participant is capable or has a legally authorized representative(s) (LAR[s]) capable of providing a signed informed consent which includes compliance with the requirements and restrictions listed in the ICF

Who cannot take part

  • Planned or anticipated medical or surgical procedure, including dental procedure, during the timeframe of the study conduct
  • Transfusion of blood, blood products (including immune globulin), or plasmapheresis within 4 weeks prior to screening
  • Change in current ITP therapy (e.g., prednisone, methylprednisone, mycophenolate, dapsone, danazol, azathioprine, or TPO receptor agonist) or dose within 4 weeks prior to screening
  • Receipt of dexamethasone within 4 weeks prior to screening
  • Receipt of rituximab or an anti-CD20 agent within 6 months prior to screening
  • Receipt of an neonatal Fc receptor (FcRn) inhibitor within 12 weeks prior to screening
  • Receipt of IVIg within 4 weeks prior to screening
  • Receipt of another investigational drug within 4-weeks or 5 half-lives (whichever is longer) prior to screening
  • Concurrent treatment with other monoclonal antibody and/or Fc therapies
  • Current or past history (within 12 months of screening) of alcohol, drug, or medication abuse. Positive urine drug screen at screening visit
  • Pregnant or lactating women and those intending to become pregnant during the study or are unwilling to apply an effective birth control method (such as implants, injectables, combined oral contraceptives, intrauterine devices [IUDs], sexual abstinence, or vasectomized partner) up to 90 days after last study drug administration
  • Secondary forms of ITP (e.g., ITP secondary to infection, autoimmune diseases, lymphoproliferative diseases and medications)
  • History of splenectomy
  • History of malignancy, unless the participant received treatment with curative intent. Participants with fully excised non-melanoma skin cancer or cervical cancer are allowed
  • History of solid organ transplant
  • Clinically significant active or chronic uncontrolled bacterial, viral, or fungal infection at screening, including active viral infection at screening
  • Any medical condition that, in the opinion of the investigator, would interfere with study evaluations or procedures, and/or put the participant at increased risk
  • Any of the following at screening:; Active Hepatitis B Virus (HBV): Hepatitis surface antigen (HBsAg) positive; Active Hepatitis C Virus (HCV): serology positive for HCV-antibody; Human Immunodeficiency Virus (HIV) positive serology
  • A known allergy to study drug and/or any of its components
  • Other significant organ dysfunction, including but not limited to, hematologic, renal, or hepatic dysfunction, as evidenced by:; Absolute neutrophil count ≤ 1.5 x 109 /L; Hemoglobin (Hgb) < 9 g/dL; Aspartate aminotransaminase (AST) and/or alanine aminotransferase (ALT) ≥ 2 x the upper limit of normal (ULN),; Albumin ≤ 3 g/dL; Total bilirubin ≥ 1.5 x ULN; Estimated glomerular filtration rate < 50 mL/min/1.73m2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) method
  • ECG findings of QTcF > 450 msec (males) or > 470 msec (females), poorly controlled atrial fibrillation or other clinically significant abnormalities
  • Poor venous access

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Where in United States

Also in 3 other countries, 10 sites

  • Beth Israel Deaconess Medical CenterBoston, United StatesContact: Rushad Patell, MDTaking people
  • East Carolina UniversityGreenville, United StatesContact: Sue Ann Joyner JoynerTaking people
  • Georgetown University Medical CenterWashington D.C., United StatesContact: Jennifer SteffenTaking people

About the trial

What the trial wants to find out

The purpose of the study is to evaluate the safety of NVG-2089 and to evaluate how well patients respond to this investigational treatment. NVG-2089 is a new drug that is being developed for treating patients with ITP. NVG-2089 is designed to mimic the effects of a protein called IVIg. NVG-2089 is designed to help the immune system by attaching (binding) to certain receptors in the body and activating them, which helps reduce inflammation and supports how the immune system works.

The group in the trial

  • NVG-2089Treatment being tested

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
An Open-Label, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous NVG-2089 in Participants With Immune Thrombocytopenia
Plain-language title
Testing NVG-2089 given by infusion for adults with immune thrombocytopeniaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT07095127, who can take part
Record updated
14 September 2026